HIV Infections Clinical Trial
Official title:
HIV Prevention With the Mentally Ill: Motivation-Skills
The purpose of this study is to determine whether motivational interviewing and skills building interventions reduce HIV risk behavior for adults with serious and persistent mental illness.
Our long-term objective is to reduce the incidence of HIV for people with serious and
persistent mental illness (SMI) by developing an effective primary and secondary HIV risk
reduction intervention for this population which can be easily delivered in the "real world"
settings in which patients routinely receive care. Research findings document that the
incidence of HIV infection, sexually transmitted diseases, and sexual and drug use behaviors
are high among people with serious mental illness, as evidenced by rates of HIV infection
and other sexually-transmitted diseases (STDs). A variety of factors underlie risky
behaviors for the SMI, including cognitive impairment, poor judgment, affective instability
and impulsiveness.
Skills-building (SB) HIV risk reduction interventions, typically delivered in a small group
formats, have had modest success in increasing HIV-related knowledge and improving risk
reduction skills for people with SMI, although these effects are transient. As
skills-building interventions are currently the standard of care in most research and
clinical settings for HIV prevention, it is important to identify new ways to augment these
interventions.
A relatively new and promising addition to the armamentarium of individualized interventions
is Motivational Interviewing (MI). MI is an approach designed to reduce ambivalence and
enhance intrinsic motivation to change problematic behaviors. Previous researchers have
noted effects for both SB and MI interventions independently, however, these effects tend to
be fairly modest. Integrating these approaches in a systematized way allows us to test the
degree to which this combination is useful, given that both motivation and skills are
clearly important in effecting health behavior change.
Our specific primary aims are the following:
1. To adapt SB and MI interventions for HIV risk reduction for men and women with serious
and persistent mental illness (SMI).
Interventions for HIV risk reduction for people with SMI are typically offered in a
group format and focus primarily on skills-building. We have developed and refined a
brief, individually-tailored skills-building intervention (SB Intervention), based on
these existing manuals. We have also adapted and refined a brief individually-tailored
Motivational Interviewing intervention to target HIV risk behaviors, incorporating
skills-building techniques analogous to those in the SB intervention, resulting in a
Motivational-Interviewing & Skills-Building Intervention (SB-MI Intervention).
Adaptation and refinement of the SB and SB-MI interventions was informed by consulting
with experts in MI, SMI, and HIV risk reduction, eliciting feedback from advisory
boards of providers and consumers, and conducting feedback interviews with participants
who have completed participation in the study.
2. To pilot test and obtain preliminary data with regard to the feasibility of our
interventions and the differences in outcome associated with our SB and SB-MI
interventions for reduction of HIV-related risk behaviors in a cohort of SMI adults.
Comparison of SB and SB-MI interventions in the proposed pilot study will allow us to
assess the degree to which incorporation of motivational techniques are helpful in
augmenting skills-building interventions for HIV risk reduction for people with SMI.
These preliminary analyses will inform our need to refine the adapted interventions (SB
and SB-MI).
3. To offer HIV counseling and testing for at-risk individuals with SMI, with an emphasis
on connecting participants to appropriate medical and mental health services.
To date, increasing rates of HIV counseling and testing for the SMI has not been a
primary focus of clinical research, which we believe to be a significant public health
deficit. As part of both of our interventions we are providing information about HIV
counseling and testing services to those participants not identified as
HIV-seropositive and encouraging them to access these services. We are then tracking
the degree to which participants follow up on these referrals as part of our follow-up
evaluations. This will allow us to test the degree to which our interventions are
helpful in increasing rates of HIV testing.
4. To begin to explore the relationships between participant characteristics, HIV risk
behaviors, and response to our interventions.
One of the unique features of our intervention is that it assumes an individually-tailored
approach, which can address unique patient characteristics inherent in a heterogeneous
sample. Indeed, using a heterogeneous sample greatly facilitates our primary long-term
objective, which is to develop useable interventions that can be adapted in real-world
settings. This project will allow us to begin to identify those characteristics that are
likely to be associated with more positive outcomes (i.e. greater risk reduction, increased
rates of HIV testing).
;
Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT05454514 -
Automated Medication Platform With Video Observation and Facial Recognition to Improve Adherence to Antiretroviral Therapy in Patients With HIV/AIDS
|
N/A | |
| Completed |
NCT03760458 -
The Pharmacokinetics, Safety, and Tolerability of Abacavir/Dolutegravir/Lamivudine Dispersible and Immediate Release Tablets in HIV-1-Infected Children Less Than 12 Years of Age
|
Phase 1/Phase 2 | |
| Completed |
NCT03141918 -
Effect of Supplementation of Bioactive Compounds on the Energy Metabolism of People Living With HIV / AIDS
|
N/A | |
| Completed |
NCT03067285 -
A Phase IV, Open-label, Randomised, Pilot Clinical Trial Designed to Evaluate the Potential Neurotoxicity of Dolutegravir/Lamivudine/Abacavir in Neurosymptomatic HIV Patients and Its Reversibility After Switching to Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide. DREAM Study
|
Phase 4 | |
| Recruiting |
NCT04579146 -
Coronary Artery Disease (CAD) in Patients HIV-infected
|
||
| Completed |
NCT06212531 -
Papuan Indigenous Model of Male Circumcision
|
N/A | |
| Active, not recruiting |
NCT03256422 -
Antiretroviral Treatment Taken 4 Days Per Week Versus Continuous Therapy 7/7 Days Per Week in HIV-1 Infected Patients
|
Phase 3 | |
| Completed |
NCT03256435 -
Retention in PrEP Care for African American MSM in Mississippi
|
N/A | |
| Completed |
NCT00517803 -
Micronutrient Supplemented Probiotic Yogurt for HIV/AIDS and Other Immunodeficiencies
|
N/A | |
| Active, not recruiting |
NCT03572335 -
Systems Biology of Diffusion Impairment in Human Immunodeficiency Virus (HIV)
|
||
| Completed |
NCT04165200 -
Fecal Microbiota Transplantation as a Therapeutic Strategy for Patients Infected With HIV
|
N/A | |
| Recruiting |
NCT03854630 -
Hepatitis B Virus Vaccination in HIV-positive Patients and Individuals at High Risk for HIV Infection
|
Phase 4 | |
| Terminated |
NCT03275571 -
HIV, Computerized Depression Therapy & Cognition
|
N/A | |
| Completed |
NCT02234882 -
Study on Pharmacokinetics
|
Phase 1 | |
| Completed |
NCT01618305 -
Evaluating the Response to Two Antiretroviral Medication Regimens in HIV-Infected Pregnant Women, Who Begin Antiretroviral Therapy Between 20 and 36 Weeks of Pregnancy, for the Prevention of Mother-to-Child Transmission
|
Phase 4 | |
| Recruiting |
NCT05043129 -
Safety and Immune Response of COVID-19 Vaccination in Patients With HIV Infection
|
||
| Not yet recruiting |
NCT05536466 -
The Influence of Having Bariatric Surgery on the Pharmacokinetics, Safety and Efficacy of the Novel Non-nucleoside Reverse Transcriptase Inhibitor Doravirine
|
N/A | |
| Recruiting |
NCT04985760 -
Evaluation of Trimer 4571 Therapeutic Vaccination in Adults Living With HIV on Suppressive Antiretroviral Therapy
|
Phase 1 | |
| Completed |
NCT05916989 -
Stimulant Use and Methylation in HIV
|
||
| Terminated |
NCT02116660 -
Evaluation of Renal Function, Efficacy, and Safety When Switching From Tenofovir/Emtricitabine Plus a Protease Inhibitor/Ritonavir, to a Combination of Raltegravir (MK-0518) Plus Nevirapine Plus Lamivudine in HIV-1 Participants With Suppressed Viremia and Impaired Renal Function (MK-0518-284)
|
Phase 2 |